File Download
Links for fulltext
(May Require Subscription)
- Find via
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: Efficacy and safety of every-2-weeks cetuximab combined with FOLFOX or FOLFIRI as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (mCRC): an Asia-Pacific nonrandomized phase II study (APEC)
| Title | Efficacy and safety of every-2-weeks cetuximab combined with FOLFOX or FOLFIRI as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (mCRC): an Asia-Pacific nonrandomized phase II study (APEC) |
|---|---|
| Authors | |
| Keywords | Medical sciences Oncology medical sciences Radiology and nuclear medicine pharmacy and pharmacology biology Cytology and histology |
| Issue Date | 2013 |
| Publisher | American Society of Clinical Oncology. The Journal's web site is located at http://www.jco.org/ |
| Citation | The 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL., 31 May-4 June 2013. In Journal of Clinical Oncology, 2013, v. 31 n. 15 suppl., abstract no. e14501 How to Cite? |
| Abstract | BACKGROUND: Randomized studies have shown that weekly cetuximab added to first-line FOLFOX or FOLFIRI improves clinical outcome in patients (pts) with KRAS wild-type (wt) mCRC. This Asia-Pacific multicenter study investigated FOLFOX or FOLFIRI + every 2 weeks cetuximab (C) as first-line therapy in pts with KRAS wt mCRC ... |
| Description | This abstract will not be presented at the 2013 ASCO Annual Meeting but has been published in conjunction with the meeting. Open Access Journal |
| Persistent Identifier | http://hdl.handle.net/10722/186974 |
| ISSN | 2021 Impact Factor: 50.717 2020 SCImago Journal Rankings: 10.482 |
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Cheng, AL | en_US |
| dc.contributor.author | Cornelio, GH | en_US |
| dc.contributor.author | Shen, L | en_US |
| dc.contributor.author | Price, TJ | en_US |
| dc.contributor.author | Yang, TS | en_US |
| dc.contributor.author | Chung, IJ | en_US |
| dc.contributor.author | Dai, G | en_US |
| dc.contributor.author | Lin, JK | en_US |
| dc.contributor.author | Sharma, A | en_US |
| dc.contributor.author | Yeh, KH | en_US |
| dc.contributor.author | Ma, B | en_US |
| dc.contributor.author | Zaatar, A | en_US |
| dc.contributor.author | Guan, ZZ | en_US |
| dc.contributor.author | Masood, N | en_US |
| dc.contributor.author | Srimuninnimit, V | en_US |
| dc.contributor.author | Yau, TCC | en_US |
| dc.contributor.author | Sarholz, B | en_US |
| dc.contributor.author | Lim, RSC | en_US |
| dc.date.accessioned | 2013-08-20T12:26:29Z | - |
| dc.date.available | 2013-08-20T12:26:29Z | - |
| dc.date.issued | 2013 | en_US |
| dc.identifier.citation | The 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL., 31 May-4 June 2013. In Journal of Clinical Oncology, 2013, v. 31 n. 15 suppl., abstract no. e14501 | en_US |
| dc.identifier.issn | 0732-183X | - |
| dc.identifier.uri | http://hdl.handle.net/10722/186974 | - |
| dc.description | This abstract will not be presented at the 2013 ASCO Annual Meeting but has been published in conjunction with the meeting. | - |
| dc.description | Open Access Journal | - |
| dc.description.abstract | BACKGROUND: Randomized studies have shown that weekly cetuximab added to first-line FOLFOX or FOLFIRI improves clinical outcome in patients (pts) with KRAS wild-type (wt) mCRC. This Asia-Pacific multicenter study investigated FOLFOX or FOLFIRI + every 2 weeks cetuximab (C) as first-line therapy in pts with KRAS wt mCRC ... | - |
| dc.language | eng | en_US |
| dc.publisher | American Society of Clinical Oncology. The Journal's web site is located at http://www.jco.org/ | - |
| dc.relation.ispartof | Journal of Clinical Oncology | en_US |
| dc.subject | Medical sciences | - |
| dc.subject | Oncology medical sciences | - |
| dc.subject | Radiology and nuclear medicine pharmacy and pharmacology biology | - |
| dc.subject | Cytology and histology | - |
| dc.title | Efficacy and safety of every-2-weeks cetuximab combined with FOLFOX or FOLFIRI as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (mCRC): an Asia-Pacific nonrandomized phase II study (APEC) | en_US |
| dc.type | Conference_Paper | en_US |
| dc.identifier.email | Yau, TCC: tyaucc@hku.hk | en_US |
| dc.identifier.authority | Yau, TCC=rp01466 | en_US |
| dc.description.nature | link_to_OA_fulltext | - |
| dc.identifier.hkuros | 217111 | en_US |
| dc.identifier.volume | 31 | en_US |
| dc.identifier.issue | 15 suppl. | - |
| dc.publisher.place | United States | - |
| dc.customcontrol.immutable | sml 131016 | - |
| dc.identifier.issnl | 0732-183X | - |